image: By integrating controlled ligand presentation, compliant viscoelastic mechanics, and robust wet adhesion into a single minimally invasive format, the platform addresses key barriers to pulmonary cell delivery—rapid washout/short residence on a moist, dynamically moving surface and the resulting loss of effective local exposure—while preserving 3D microenvironmental support for MSC function.
Credit: Cong Ye, Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University.
ALI, characterized by uncontrolled inflammation, oxidative stress, and fibrotic remodeling, remains a leading cause of morbidity and mortality worldwide. While MSCs hold promise for pulmonary repair due to their immunomodulatory and paracrine capabilities, clinical translation has been hindered by rapid clearance of systemically delivered cells and loss of therapeutic phenotype in conventional 2D culture. The new platform, led by Drs. Weixi Wang and Cong Ye, solves these issues through a bioengineered design that integrates 3D MSC culture with localized, adhesive delivery.
The GelMA@hMSCs-Alg-RGD system features a modular, mechanotransduction-aware architecture optimized for lung tissue compatibility. Human MSCs (hMSCs) are seeded onto RGD (Arg-Gly-Asp)-functionalized alginate microbeads, which provide a low-tension 3D microenvironment. Key advantages include: (1) Controlled integrin engagement: RGD ligands support MSC adhesion and survival without inducing excessive cytoskeletal tension, preserving their immunomodulatory phenotype; (2) 3D culture boosts paracrine potency, antioxidative capacity, and resistance to apoptosis compared to 2D-cultured MSCs; (3) Uniform microbeads (50–120 μm) with high sphericity ensure homogeneous cell attachment and mass transport.
The alginate microbeads are encapsulated within a dopamine-modified gelatin methacrylate (GelMA-DA) hydrogel, forming a thin, adhesive layer that anchors the composite to the wet, dynamically moving lung surface. Critical properties include: (1) Photopolymerizes within 1–3 minutes under UV light, enabling minimally invasive delivery; (2) Catechol chemistry mediates strong underwater bonding to lung tissue, resisting respiratory motion and fluid flushing; (3) Viscoelastic properties match healthy lung tissue stiffness, avoiding pathological tension on resident or therapeutic cells; (4) Gradual breakdown over the therapeutic window ensures sustained MSC retention while minimizing long-term tissue burden.
The platform exerts therapeutic effects through multiple interconnected mechanisms: (1) Enhanced MSC paracrine activity; (2) Suppression of fibrotic remodeling; (3) Prolonged pulmonary retention.
The researchers tested the platform in a lipopolysaccharide (LPS)-induced murine ALI model, achieving significant therapeutic outcomes: (1) Marked decreases in pro-inflammatory cytokines (IL-6, TNF-α, IL-1β) and myeloperoxidase (MPO) activity (a surrogate for neutrophil infiltration); (2) Lower malondialdehyde (MDA) levels and enhanced superoxide dismutase (SOD) activity, mitigating lipid peroxidation; (3) Decreased lung wet/dry weight ratio, indicating reduced vascular leakage; (4) Preserved alveolar architecture, thinner septa, and reduced collagen deposition (confirmed by H&E and Masson’s trichrome staining); (5) Reduced neutrophil counts and robust M1→M2 macrophage polarization; (6) Improved mortality outcomes compared to control and unencapsulated MSC groups.
GelMA@hMSCs-Alg-RGD addresses unmet needs in ALI therapy by combining localized delivery, MSC phenotype preservation, and mechanotransduction tuning. Its modular design—based on clinically approved alginate and gelatin—supports translational potential, with scalable fabrication and standardized quality control.
Future research will focus on: (1) Validating efficacy in large animal models and clinical trials; (2) Adapting the platform for other inflammatory lung diseases (e.g., ARDS, pulmonary fibrosis); (3) Incorporating additional therapeutic agents (e.g., growth factors, anti-inflammatory drugs) for synergistic effects; (4) Optimizing delivery via endoscopic or aerosol routes to enhance clinical applicability.
This bioengineered “sandwich” system represents a paradigm shift in MSC-based regenerative medicine, demonstrating that mechanotransduction-aware design—integrating 3D niche engineering and wet-adhesive delivery—can overcome key barriers to ALI therapy. By prolonging MSC retention and amplifying their paracrine and immunomodulatory functions, GelMA@hMSCs-Alg-RGD offers a versatile, clinically translatable platform for treating acute lung injury and potentially other inflammatory or fibrotic disorders. “Our work establishes that cells are only as potent as the microenvironments that host them," noted the study’s corresponding authors. "This strategy provides a blueprint for next-generation cell therapies that combine spatiotemporal control with mechanobiological precision.”
Authors of the paper include Xuyu Gu, Jijun Sun, Yifei Zhou, Dongning Lu, Weixi Wang, and Cong Ye.
This work was supported by the Young Scientists Fund of the National Natural Science Foundation of China (No. 82000084).
The paper, “A Mechanotransduction-Aware Strategy for Enhancing MSC Potency via 3D Culture and Localized Delivery” was published in the journal Cyborg and Bionic Systems on Mar. 24, 2026, at DOI: 10.34133/cbsystems.0552.
Journal
Cyborg and Bionic Systems